Schwartz, Anthony L. http://orcid.org/0000-0002-0407-6825
Nath, Pulak R. http://orcid.org/0000-0001-9643-5217
Allgauer, Michael
Lessey-Morillon, Elizabeth C. http://orcid.org/0000-0001-7885-6173
Sipes, John M.
Ridnour, Lisa A. http://orcid.org/0000-0001-9446-8349
Morillon II, Y. Maurice
Yu, Zhiya
Restifo, Nicholas P. http://orcid.org/0000-0003-4229-4580
Roberts, David D. http://orcid.org/0000-0002-2481-2981
Funding for this research was provided by:
National Cancer Institute (ZIA SC 009172)
Article History
Received: 3 April 2018
Accepted: 14 September 2019
First Online: 18 October 2019
Compliance with ethical standards
:
: Anthony L. Schwartz is the Chief Executive Officer and shareholder of Morphiex Biotherapeutics which holds licensing rights to the CD47 Morpholino. All other authors of this paper declare no conflicts of interest.
: Animal Studies: The B16 melanoma animal model was carried out under approved protocols (Protocol #LP-026, January 2016) following the guidelines of the National Cancer Institute’s Animal Care and Use Committee.
: Human T-cell studies: TCGA data were obtained under informed consent as described (ExternalRef removed). No new human materials for T-cell experiments were obtained, thus did not require consent or IRB review.
: C57BL/6 mice were obtained from Jackson Laboratories (Bar Harbor, ME).
: B16F10 (CRL-6475) mouse melanoma cell line was purchased from ATCC and were authenticated at the Frederick National Laboratory for Cancer Research (Frederick, MD). The origin of the T-cell lines was previously published, described and provided by the Surgery Branch, Center for Cancer Research, National Cancer Institute [CitationRef removed].